Recently, the patent rights to mRNA display technology were acquired by Bristol-Myers Squibb as a major protein design engine for the systematic development of biopharmaceuticals with high potency ...

Currently, mRNA display is a totally in vitro peptide or protein selection method. Owing to its unique features, we expect that this technique will be widely applied to investigate many different ...

Samsung Electronics Co. Ltd. 3.16% ₩378.11T ...

This valuable work presents how PRDM16 plays a critical role during colloid plexus development, through regulating BMP signaling. Solid evidence supports the context-dependent gene regulatory ...

The display industry has come a long way in recent years. With so many competing standards on the market today, it’s often hard to tell if an emerging technology is worth paying extra for.

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.